ラミブジンの中国市場

調査会社China Research and Intelligence社が発行したリサーチレポート(データ管理コード:DATA8102363)
◆英語タイトル:Investigation Report on China's Lamivudine Market, 2018-2022
◆発行会社/調査会社:China Research and Intelligence
◆商品コード:DATA8102363
◆発行日:2018年9月
◆調査対象地域:中国
◆産業分野:製薬
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,200 ⇒換算¥239,800見積依頼/購入/質問フォーム
EnterprisewideUSD3,300 ⇒換算¥359,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ラミブジンの中国市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DescriptionAt the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China. In addition, a large number of people infected with HIV and AIDS patients have not been discovered. Meanwhile, over 90 million people in China are infected with the hepatitis B virus.
Lamivudine is a major drug against the hepatitis B virus and AIDS in China. The Chinese government offers it to AIDS patients for free. Lamivudine is a nucleoside analog as well as an antiviral drug. In 1998, the FDA first approved Lamivudine as a treatment for hepatitis B. The State Food and Drug Administration (SFDA) approved the drug to be imported to China for the treatment of hepatitis B. In 1999, GlaxoSmithKline started to sell its original Lamivudine in the trade name “Heptodin” in China. More than 2 million hepatitis B patients and an unknown number of HIV-infected patients and AIDS patients are taking Heptodin in China.
By the end of 2017, more than 10 enterprises had been approved to produce Lamivudine tablets or capsules.
Lamivudine developed rapidly after it entered China. The sales volume reached CNY 307 million in 2012, declined from 2013 and fell to about CNY 159 million in 2017. The market is dominated by GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd., Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical Co., Ltd. and Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd. has the largest market share. Its sales value exceeded CNY 100 million in 2017, taking up a market share close to 67%.
Considering the large number of hepatitis B and AIDS patients in China, it is expected that the market size of China’s Lamivudine market will continue to grow.

Topics Covered:
- Development environment of China’s Lamivudine market
- Size of China’s Lamivudine market
- Competition pattern of China’s Lamivudine market
- Prices of Lamivudine in China
- Driving forces and opportunities for China’s Lamivudine market
- Prospect of China’s Lamivudine market from 2018 to 2022

*** レポート目次(コンテンツ)***

Table of Contents
1 Relevant Concepts of Lamivudine
1.1 Indications for Lamivudine
1.2 Development History of Lamivudine in China
1.3 Governmental Approval of Lamivudine in China

2 Sales of Lamivudine in China, 2013-2017
2.1 Sales Value
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Lamivudine by Dosage Form in China, 2013-2017
2.3.1 Capsules
2.3.2 Tablets

3 Analysis on Major Lamivudine Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Lamivudine Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.’s Lamivudine in China
3.3 Wellcome Foundation
3.3.1 Enterprise Profile
3.3.2 Sales of Wellcome Foundation’s Lamivudine in China
3.4 Anhui Biochem Bio-Pharmaceutical Co., Ltd.
3.5 Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd.
3.6 Beijing Winsunny Pharmaceutical Co., Ltd.

4 Prices of Lamivudine in China, 2017-2018
4.1 GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd. (Heptodin)
4.2 Wellcome Foundation
4.3 Anhui Biochem Bio-Pharmaceutical Co., Ltd. (Yinding)
4.4 Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. (Jianganling)
4.5 Beijing Winsunny Pharmaceutical Co., Ltd. (Winsunny Like)

5 Prospect of China’s Lamivudine Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Sales of Lamivudine in China, 2013-2017
Chart Sales Value of Lamivudine in Parts of China, 2013-2017
Chart Sales Volume of Lamivudine in China, 2013-2017
Chart Sales Volume of Lamivudine in Parts of China, 2013-2017
Chart Sales Value of Lamivudine Capsules in China, 2013-2017
Chart Sales Volume of Lamivudine Capsules in China, 2013-2017
Chart Sales Value of Lamivudine Tablets in China, 2013-2017
Chart Market Share of Top 5 Lamivudine Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Lamivudine Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.’s Lamivudine, 2013-2017
Chart Sales Value of Wellcome Foundation’s Lamivudine, 2013-2017
Chart Sales Value of Beijing Winsunny Pharmaceutical Co., Ltd.’s Lamivudine, 2013-2017
Chart Prices of GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.’s Lamivudine (Heptodin) in Parts of China, 2017-2018
Chart Prices of Anhui Biochem Bio-Pharmaceutical Co., Ltd.’s Lamivudine (Yinding) in Parts of China, 2017-2018
Chart Governmental Approval of Lamivudine in China
Chart Forecast on Sales Value of Lamivudine in China, 2018-2012



*** レポートのキーワード ***

ラミブジン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA8102363 )"ラミブジンの中国市場" (英文:Investigation Report on China's Lamivudine Market, 2018-2022)はChina Research and Intelligence社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。